CFDE Data Portal | Search RAB22A

	Label	Description
	RAB22A Gene (Entity type)	ENSG00000124209 - RAB22A, member RAS oncogene family
	RAB22A associations Collection (Entity type)	Associations for RAB22A_associations
	RAB22A associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 3 V 2 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE248769 1 V 0 SORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 FOXA1 inhibition prostate gland Ivermectin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE109285 3 V 2 GLUCAGON MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

RAB22A

ENSG00000124209 - RAB22A, member RAS oncogene family

RAB22A associations

Associations for RAB22A_associations

RAB22A associations.tsv

A file from IDG as part of the Harmonizome project

GSE195663 cisplatin 7 v 1 human dn

A Gene Set from LINCS

GSE229973 3 V 2 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

A Gene Set from LINCS

GSE248769 1 V 0 SORAFENIB HUMAN UP

A Gene Set from LINCS

GSE169356 ivermectin prostate gland 0 v 1 human up

A Gene Set from LINCS

GSE169356 FOXA1 inhibition prostate gland Ivermectin 0 v 1 human up

A Gene Set from LINCS

GSE109285 3 V 2 GLUCAGON MOUSE UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.